Cell Therapy – Talk Bio

Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey

3 days ago talkbio0Tagged Bayer, bemdaneprocel, biotech partnerships, BlueRock Therapeutics, Cell Therapy, Identifier, Parkinson 's disease, Phase 3 trials, Regenerative Medicine, RMAT

cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine

Galapagos Walks Back Split Plans, Raising Questions Over Cell Therapy Assets

4 weeks ago talkbio0Tagged Appointments, Automobiles, biotech industry, Cell Therapy, CEO, Company Split, Galapagos, spinoff, T business

Galapagos; company split; cell therapy; spinoff; CEO appointment; biotech industry; CAR T business

Galapagos Reconsiders Company Split After Market Developments

4 weeks ago talkbio0Tagged Cell Therapy, Company Split, conditions, Drug Development, Galapagos, Leadership Change, Market, strategic review

Galapagos; company split; cell therapy; drug development; strategic review; leadership change; market conditions

Biotech stocks plunge and industry figures left to wonder after Prasad’s FDA appointment

1 month ago talkbio0Tagged Appointments, Cell Therapy, figures, Industry, Market, Prasad, stocks, United States Food and Drug Administration

United States Food and Drug Administration, Industry, Prasad, Appointments, stocks, Cell Therapy, Market, figures

BMS to close Illinois site as part of cell therapy manufacturing consolidation

1 month ago talkbio0Tagged Acquisition, Cell Therapy, Financial cost, Libertyville Illinois, manufacturing consolidation, Myers, Novartis, squibb, Viral Vector

Bristol Myers Squibb, viral vector production, Libertyville Illinois, manufacturing consolidation, Novartis acquisition, cell therapy, cost cuts

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

1 month ago talkbio0Tagged 32%, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, CAR-T, Cell Therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, Neoplasms, Reindeer, Staff, United States Food and Drug Administration

Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%

Cartesian reveals long-term mid-stage data for cell therapy in myasthenia gravis

2 months ago talkbio0Tagged Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, Cartesian, Cell Therapy, Long-term, Myasthenia Gravis

Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, Myasthenia Gravis, Cell Therapy, Long-term, Cartesian

Neurona nabs $102M to launch pivotal trial of epilepsy cell therapy

2 months ago talkbio0Tagged Cell Therapy, drug-resistant, Epilepsy, Identifier, MTLE, RMAT

MTLE, Epilepsy, Cell Therapy, RMAT, Identifier, drug-resistant

Cellares’ cell therapy factory-in-a-box scores coveted advanced manufacturing technology tag from FDA

2 months ago talkbio0Tagged Advanced Manufacturing Technology, Biologics License Application, Cell Shuttle, Cell Therapy, Cellares, Identifier, Investigational New Drugs, production, Technology, United States Food and Drug Administration

Cell Therapy, Advanced Manufacturing Technology, United States Food and Drug Administration, Technology, Identifier, Cell Shuttle, production, Cellares, Biologics License Application, Investigational New Drugs

Back to the drawing board for Vertex’s ‘cells plus device’ diabetes programme

2 months ago talkbio0Tagged Cell Therapy, Clinical Trials, Failure (biologic function), implantable device, Insulin, production, VX-264, zimislecel

Vertex Pharmaceuticals, VX-264, type 1 diabetes, cell therapy, implantable device, clinical trial failure, zimislecel, insulin production